Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

BACKGROUND: We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with an encouraging rate of pathologic response. Building on these results, and promising data for nivolumab plus ipilimumab (...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuss, Joshua E, Anagnostou, Valsamo, Cottrell, Tricia R, Smith, Kellie N, Verde, Franco, Zahurak, Marianna, Lanis, Mara, Murray, Joseph C, Chan, Hok Yee, McCarthy, Caroline, Wang, Daphne, White, James R, Yang, Stephen, Battafarano, Richard, Broderick, Stephen, Bush, Errol, Brock, Malcolm, Ha, Jinny, Jones, David, Merghoub, Taha, Taube, Janis, Velculescu, Victor E, Rosner, Gary, Illei, Peter, Pardoll, Drew M, Topalian, Suzanne, Naidoo, Jarushka, Levy, Ben, Hellmann, Matthew D, Brahmer, Julie R, Chaft, Jamie E, Forde, Patrick M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488786/
https://www.ncbi.nlm.nih.gov/pubmed/32929052
http://dx.doi.org/10.1136/jitc-2020-001282

Ejemplares similares

Ejemplares similares